NCT07233096 Rectus-Intercostal Fascial Plane Block for Liver Transplantation Donors
| NCT ID | NCT07233096 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istinye University |
| Condition | Liver Transplantation |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2025-12-22 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 64 participants in total. It began in 2025-12-22 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Postoperative pain control plays a crucial role in enhancing recovery and improving early mobilization in living liver donors. The rectus-intercostal fascial plane (RIFP) block is a novel ultrasound-guided regional anesthesia technique that provides anterior abdominal wall analgesia by targeting the intercostal nerves between the rectus abdominis and intercostal muscle fascia. This prospective, randomized controlled clinical study aims to evaluate the postoperative analgesic efficacy and opioid-sparing effects of the RIFP block compared with standard intravenous analgesia in living liver donors undergoing donor hepatectomy. Participants will be randomly assigned to two groups: Group 1 (RIFP Block): Patients receiving an ultrasound-guided rectus-intercostal fascial plane block using 20 mL of 0.25% bupivacaine at the end of surgery, in addition to standard IV PCA (morphine). Group 2 (Control): Patients receiving only standard IV PCA (morphine) without regional block.
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 75 years * Patients with American Society of Anesthesiology (ASA) physical status I-II * Patients scheduled for a living donor hepatectomy Exclusion Criteria: * Allergy to local anesthetics * Coagulopathy * Skin infection at the block area * Advanced renal failure * Chronic pain syndromes * Alcohol or drug abuse * Psychiatric disorders
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07233096 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Liver Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07233096 currently recruiting?
Yes, NCT07233096 is actively recruiting participants. Contact the research team at taylansah@hotmail.com for enrollment information.
Where is the NCT07233096 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07233096 clinical trial?
NCT07233096 is sponsored by Istinye University. The trial plans to enroll 64 participants.